IGM BIOSCIENCES, INC.

(IGMS)
  Report
Real-time Estimate Cboe BZX  -  03:51 2022-07-06 pm EDT
20.18 USD   +2.91%
06/24IGM BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell 3000 Value Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell Small Cap Comp Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Non-Voting Common Stock of IGM Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2022.

05/29/2022 EDT

Certain Non-Voting Common Stock of IGM Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2022. These Non-Voting Common Stock will be under lockup for 60 days starting from 30-MAR-2022 to 29-MAY-2022. Details: directors and officers (the “Lock-Up Parties”) and the company have agreed that, without the prior written consent of the representatives on behalf of the underwriters, the company and they will not, and will not publicly disclose an intention to, during the period ending 60 days after the date of this prospectus supplement (the “restricted period”) sell, offer to sell, contract to sell or lend any shares of common stock or any options, warrants or rights to acquire shares of common stock or any securities exchangeable or exercisable for or convertible into shares of common stock, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into shares of common stock (“Related Securities”), effect any short sale, or establish or increase any “put equivalent position” (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any “call equivalent position” (as defined in Rule 16a-1(b) under the Exchange Act) of any common stock or Related Securities, pledge, hypothecate or grant any security interest in any common stock or Related Securities, in any other way transfer or dispose of any common stock or Related Securities, enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of shares of common stock or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise, announce the offering of any shares of common stock or Related Securities, submit or file any registration statement under the Securities Act in respect of any common stock or Related Securities (other than the common stock offered hereby), effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding common stock or publicly announce any intention to do any of the foregoing.


© S&P Capital IQ 2022
All news about IGM BIOSCIENCES, INC.
06/24IGM BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell 3000 Value Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell Small Cap Comp Value Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell Microcap Value Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell 2000 Value Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell Microcap Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell 3000E Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell 3000E Growth Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell 2500 Value Index
CI
06/24IGM BIOSCIENCES, INC.(NASDAQGS : IGMS) added to Russell 3000E Value Index
CI
More news
Analyst Recommendations on IGM BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 41,7 M - -
Net income 2022 -193 M - -
Net cash 2022 355 M - -
P/E ratio 2022 -4,09x
Yield 2022 -
Capitalization 834 M 834 M -
EV / Sales 2022 11,5x
EV / Sales 2023 68,2x
Nbr of Employees 216
Free-Float 38,0%
Chart IGM BIOSCIENCES, INC.
Duration : Period :
IGM Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IGM BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 19,61 $
Average target price 49,56 $
Spread / Average Target 153%
EPS Revisions
Managers and Directors
Fred M. Schwarzer Chairman & Chief Executive Officer
Misbah Tahir Chief Financial Officer
Michael D. Loberg Chairman
Bruce A. Keyt Chief Scientific Officer
T. S. Harigopal Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
IGM BIOSCIENCES, INC.-33.14%834
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.67%49 127
BIONTECH SE-37.54%39 133